Unbiased Analysis of Today's Healthcare Issues
Alan Balch, PhD, discusses the Institute for Clinical and Economic Review’s (ICER’s) Value Assessment Framework tool that aims to provide stakeholders in healthcare with evidence to make more informed decisions regarding new cancer therapies. Dr Balch also considers limitations to the tool’s effectiveness. Plus, he even discusses why if we lived life using a strict…
The Institute for Clinical and Economic Research aims to measure the value of drugs and aims to reduce the price of treatments that they deem to be low-value. Is this simply an academic exercises, or are payers paying attention? An article in CNBC sheds some light on the topic: Asked about that analysis, Miller said: “We…
In recent years, a number of organizations have developed value frameworks to assess new treatments. These organizations include the Institute for Clinical and Economic Review (ICER), Memorial Sloan Kettering Memorial Cancer Center (Drug Abacus), American Society for Clinical Oncologists (ASCO), National Comprehensive Cancer Network (NCCN), European Society of Medical Oncology (Magnitude of Clinical Benefit Scale).…
The National Institute for Health and Care Excellence (NICE) claims that although cost-effectiveness is highly valued in its health technology appraisal process, it sates that there are other factors considered relevant. However, no explicit weight is assigned to these other factors. Do they matter? A paper by Dakin et al. (2015) tries to answer this question by looking…